Update on lymphocyte-activation gene 3 (LAG-3) in cancers: from biological properties to clinical applications
Author:
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
General Medicine,General Medicine
Reference124 articles.
1. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥50;Reck;J Clin Oncol,2021
2. Immune checkpoint blockade in cancer therapy;Postow;J Clin Oncol,2015
3. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer;Brahmer;N Engl J Med,2015
4. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer;Borghaei;N Engl J Med,2015
5. The landscape of immune checkpoints expression in non-small cell lung cancer: a narrative review;Liu;Transl Lung Cancer Res,2021
Cited by 11 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study;Journal of Clinical Oncology;2024-06-10
2. Immune checkpoint inhibitors: breakthroughs in cancer treatment;Cancer Biology & Medicine;2024-05-24
3. Bibliometric analysis of evolutionary trajectory and prospective directions of LAG-3 in cancer;Frontiers in Immunology;2024-02-08
4. Tissue biomarkers of immune checkpoint inhibitor therapy;Immunology & Cell Biology;2024-01-16
5. Mesenchymal ovarian cancer cells promote CD8+ T cell exhaustion through the LGALS3-LAG3 axis;npj Systems Biology and Applications;2023-12-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3